BioCentury | Mar 24, 2021
Deals

March 23 Quick Takes: Moulder’s Zenas launches; plus PhoreMost, 1910 Genetics, XyloCor and Catalent

...including a lead mAb for thyroid eye disease. Moulder’s family office, Tellus BioVentures LLC, and Fairmount Funds...
BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...Surveyor Capital, Farallon Capital Management, BVF Partners, Boxer Capital, Sphera Healthcare, Woodline Partners, Suvretta Capital, Fairmount Funds...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...staff from both companies. A crossover syndicate is investing $91 million into the union; leader Fairmount Funds...
Items per page:
1 - 3 of 3
BioCentury | Mar 24, 2021
Deals

March 23 Quick Takes: Moulder’s Zenas launches; plus PhoreMost, 1910 Genetics, XyloCor and Catalent

...including a lead mAb for thyroid eye disease. Moulder’s family office, Tellus BioVentures LLC, and Fairmount Funds...
BioCentury | Mar 19, 2021
Product Development

Point’s SPAC, Aktis’ A round add to cash flow for radiotherapies: Data Byte

...Surveyor Capital, Farallon Capital Management, BVF Partners, Boxer Capital, Sphera Healthcare, Woodline Partners, Suvretta Capital, Fairmount Funds...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

...staff from both companies. A crossover syndicate is investing $91 million into the union; leader Fairmount Funds...
Items per page:
1 - 3 of 3